Gut Akkermansia muciniphila , Prevotellaceae , and Enterobacteriaceae spp. as Possible Markers in Women-Related Nutritional and Clinical Trials: Familial Mediterranean Fever Disease
Open Access
- 1 April 2024
- journal article
- research article
- Published by SAGE Publications in Women's Health Reports
- Vol. 5 (1) , 785-793
Abstract
Studies have shown that the gut microbiota of healthy men and men with familial Mediterranean fever (FMF) disease respond differently to placebo. Given the fact that the composition of the gut microbiota is different in men and women, this study aimed to describe in detail the placebo response of the gut microbiota in healthy and FMF women. The bacterial response to placebo was fully evaluated on a previous PhyloChip™ DNA microarray-based assay (GEO Series; accession number GSE111835). The change in the total number of operational taxonomic units in healthy women exposed to placebo is more than that of healthy men, in contrast to FMF people (704 vs. 140 and 409 vs. 7560, respectively [p < 0.05]). Gut Firmicutes diversities are more sensitive to placebo, whereas Akkermansia muciniphila remained unchanged after the placebo administration for both healthy and FMF people. Gut Prevotellaceae and Enterobacteriaceae diversities of healthy subjects and FMF women are also almost unchanged from placebo. Meanwhile, only 56.35% of gut Enterobacteriaceae diversities in FMF men were placebo resistant. The response to a placebo varies depending on a person's gender and health status. Healthy and FMF women's placebo study groups could be avoided by excluding placebo-sensitive 704 of 18,725 and 409 of 18,725 bacterial diversities, respectively. Because the placebo causes changes in all gut bacterial phyla in healthy and FMF women, and only the representatives of Enterobacteriaceae and Prevotellaceae families and A. muciniphila spp. are not affected by placebo, these bacteria can be considered as possible markers in women-related nutritional/clinical trials. Data on the response of the gut microbiota in healthy women to placebo might be used in studies of diseases other than FMF. The response of gut bacteria from different taxonomic affiliations to placebo may provide a basis for uncovering the role of these bacteria in the gut-brain axis.Keywords
This publication has 55 references indexed in Scilit:
- Challenges for heat stress: Intestinal culturable bacteria of Lohmann Brown chickensResearch in Veterinary Science, 2024
- Understanding the Diversity and Roles of the Ruminal MicrobiomeJournal of Microbiology, 2024
- Rational management of the plant microbiome for the Second Green RevolutionPlant Communications, 2024
- Informed Consent for Placebo‐Controlled Trials: Do Ethics and Science Conflict?Ethics & Human Research, 2022
- Solutions in microbiome engineering: prioritizing barriers to organism establishmentThe ISME Journal, 2021
- The Effect of Immunobiotic/Psychobiotic Lactobacillus acidophilus Strain INMIA 9602 Er 317/402 Narine on Gut Prevotella in Familial Mediterranean Fever: Gender-Associated EffectsProbiotics and Antimicrobial Proteins, 2021
- Combined use of eBeam irradiation and the potential probiotic Lactobacillus rhamnosus Vahe for control of foodborne pathogen Klebsiella pneumoniaeAnnals of Microbiology, 2019
- Effects of Probiotic Lactobacillus acidophilus Strain INMIA 9602 Er 317/402 and Putative Probiotic Lactobacilli on DNA Damages in the Small Intestine of Wistar Rats In VivoProbiotics and Antimicrobial Proteins, 2018
- The relativity of ‘placebos’: defending a modified version of Grünbaum’s definitionSynthese, 2016
- Identification of MEFV-Independent Modifying Genetic Factors for Familial Mediterranean FeverThe American Journal of Human Genetics, 2000